ESMO 2021 VL

Cabazitaxel as a Third-Line Treatment After Docetaxel and an Androgen Receptor Targeting Agent in mCRPC Patients – Alicia Morgans

Details
Alicia Morgans joins Oliver Sartor in this UroToday conversation highlighting a modeling analysis of cabazitaxel compared to repeat treatment with an androgen receptor targeting agent (ARTA) among patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and the alternative ARTA. This analysis uses a hypothetical cohort of patients who are similar to t...

Enzalutamide Plus Talazoparib vs Placebo Plus Enzalutamide in Men With DDR Gene Mutations, the TALAPRO-3 Trial in mCSPC – Neeraj Agarwal

Details
Neeraj Agarwal joins Alicia Morgans for a conversation on the TALAPRO-3 data presented at the European Society of Medical Oncology (ESMO) 2021 annual meeting. The TALAPRO-3 trial is a phase 3 trial assessing enzalutamide plus talazoparib versus placebo plus enzalutamide in men with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC). They discuss how this trial fits into the l...

Practice-Changing and Emerging Treatment Strategies in Metastatic Urothelial Carcinoma - Guru Sonpavde

Details
Guru Sonpavde joins Ashish Kamat sharing takeaways from the 2021 ESMO meeting starting with practice-changing or practice reaffirming studies, followed by other emerging drugs and data. Dr. Sonpavde highlighted the landmark phase 3 EV-301 study that led to the approval of enfortumab vedotin in post-platinum and PD-1 inhibitor-treated patients with metastatic urothelial carcinoma. Among the other s...

Preliminary Results of MGC018, an anti B7-H3 Antibody Drug Conjugate in mCRPC – Eugene Shenderov

Details
Alicia Morgans and Eugene Shenderov, discuss Dr Shenderov’s recent ESMO 2021 presentation on MGCO18, an anti-B7-H3 antibody-drug conjugate. Dr. Shenderov presented preliminary results of a phase one cohort expansion, testing MGC018, an investigational ADC with a duocarmycin payload linked to an anti-B7-H3 monoclonal antibody, in patients with metastatic castration-resistant prostate cancer (mCRPC)...

Tazemetostat in Combination With Abiraterone + Prednisone or Enzalutamide in mCRPC – Wassim Abida

Details
During the European Society for Medical Oncology (ESMO) Annual Congress, Wassim Abida presented an analysis of the safety and efficacy of tazemetostat in combination with abiraterone/prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). In this UroToday discussion, Dr. Abida joins Alicia Morgans to provide a background of the study and to share the re...

Cabazitaxel in Male Patients with Chemotherapy Pre-Treated Metastatic Germ-Cell Tumors CABA-GCT - Giulia Baciarello

Details
Alicia Morgans and Giulia Baciarello, discuss the CABA-GCT Study, an academic trial looking at cabazitaxel in patients with refractory germ cell tumors. Biographies: Giulia Baciarello, MD, Medical Oncology 1, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, Italy Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Ca...

Prospective Analysis of The Effect of Germline Mutations on Outcomes for mCRPC Patients Treated With Radium-223 (PRORADIUM) – Elena Castro

Details
Elena Castro joins Alicia Morgans to discuss the PRORADIUM study, examining the effect of germline mutations on outcomes for patients treated with radium-223. The hypothesis of this study was that patients with germline mutations in HR genes may have a potentiated response to radium-223. Regulatory approved based on data from the ALSYMPCA trial, radium-223 is an alpha-emitter that induces double-s...

CheckMate 9KD Trial CohortA2 Evaluating Nivolumab + Rucaparib for Chemotherapy-Naïve mCRPC - Daniel Petrylak

Details
In this UroToday discussion, Daniel Petrylak joins Tom Keane highlighting the ESMO 2021 data on CheckMate 9KD cohort A2. This was the final analysis of nivolumab and rucaparib for chemotherapy- naïve metastatic castration-resistant prostate cancer. Biographies: Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology; Co-Leader, Cancer Signaling Networks, Yale Cancer Center,...

Cisplatin-Related Immunomodulation and Efficacy with Atezolizumab + Cisplatin Versus Carboplatin-Based Chemotherapy in Metastatic Urothelial Cancer - Matthew Galsky

Details
In this conversation with Alicia Morgans, Matthew Galsky highlights an exploratory analysis within the IMvigor130 randomized phase III study of patients with metastatic urothelial cancer who were treatment-naive. IMvigor130 was asking two separate questions, should we combine platinum-based chemotherapy with atezolizumab versus giving platinum-based chemotherapy alone, and should we give immune ch...

Sabizabulin in Men with Metastatic Castration Resistant Prostate Cancer - Mark Markowski

Details
In this UroToday discussion between Alicia Morgans and Mark Markowski, they discuss the results of a Phase 1b/2 study of sabizabulin, an androgen receptor transport disruptor, in men with metastatic castration-resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent. Sabizabulin is an oral agent that inhibits microtubule assembly as well as disrupts androgen receptor trans...
email news signup